PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
-0.08%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$2.82B
AUM Growth
+$2.82B
(-21%)
Cap. Flow
-$412M
Cap. Flow
% of AUM
-14.61%
Top 10 Holdings %
Top 10 Hldgs %
54.76%
Holding
113
New
15
Increased
15
Reduced
28
Closed
26
Top Buys
| 1 |
Edgewise Therapeutics
EWTX
|
$85M |
| 2 |
Insmed
INSM
|
$27.9M |
| 3 |
BBNX
Beta Bionics, Inc. Common Stock
BBNX
|
$19.5M |
| 4 |
Dyne Therapeutics
DYN
|
$18.5M |
| 5 |
Solid Biosciences
SLDB
|
$18.5M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$69.9M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$66.2M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$60M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$47.6M |
| 5 |
Insulet
PODD
|
$42.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
Verona Pharma
VRNA
$9.16B
| $417M | 14.72% | 6,563,340 +171,234 | +3% | +$10.9M |
|
2
Arcellx
ACLX
$3.85B
| $192M | 6.78% | 2,926,478 -552,410 | -16% | -$36.2M |
|
3
Amicus Therapeutics
FOLD
$2.34B
| $175M | 6.19% | 21,464,527 -2,781,425 | -11% | -$22.7M |
|
|
4
Edgewise Therapeutics
EWTX
$1.51B
| $144M | 5.09% | 6,547,328 +3,861,791 | +144% | +$85M |
|
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $135M | 4.77% | 2,548,445 -1,132,028 | -31% | -$60M |
|
|
6
Nuvalent
NUVL
$5.52B
| $116M | 4.09% | 1,633,968 -986,009 | -38% | -$69.9M |
|
7
Soleno Therapeutics
SLNO
$3.6B
| $108M | 3.8% | 1,506,602 +5,562 | +0.4% | +$397K |
|
|
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $104M | 3.66% | 786,358 -501,970 | -39% | -$66.2M |
|
9
MeiraGTx Holdings
MGTX
$587M
| $85.3M | 3.01% | 12,581,103 | – | – |
|
10
Artivion
AORT
$2.07B
| $68.7M | 2.43% | 2,793,703 | – | – |
|
11
Aldeyra Therapeutics
ALDX
$351M
| $53.3M | 1.88% | 9,275,851 | – | – |
|
12
Protagonist Therapeutics
PTGX
$3.67B
| $52.8M | 1.86% | 1,091,271 -180,391 | -14% | -$8.72M |
|
13
Evolus
EOLS
$494M
| $49.7M | 1.75% | 4,129,142 -1,016,704 | -20% | -$12.2M |
|
14
Immunovant
IMVT
$2.56B
| $48.6M | 1.72% | 2,844,072 +704,873 | +33% | +$12M |
|
|
15
Solid Biosciences
SLDB
$427M
| $44.1M | 1.56% | 11,906,646 +5,000,000 | +72% | +$18.5M |
|
|
CNTA
16
Centessa Pharmaceuticals
CNTA
$2.25B
| $43.7M | 1.54% | 3,040,395 -3,308,825 | -52% | -$47.6M |
|
17
Iovance Biotherapeutics
IOVA
$807M
| $42.3M | 1.5% | 12,711,788 -9,400,478 | -43% | -$31.3M |
|
18
Immatics
IMTX
$619M
| $42.3M | 1.5% | 9,383,456 | – | – |
|
19
Apogee Therapeutics
APGE
$2.17B
| $41.9M | 1.48% | 1,122,767 +75,535 | +7% | +$2.82M |
|
20
Axsome Therapeutics
AXSM
$6.05B
| $41.4M | 1.46% | 355,107 -308,967 | -47% | -$36M |
|
|
21
Insmed
INSM
$28.8B
| $38.9M | 1.37% | 509,300 +365,300 | +254% | +$27.9M |
|
22
Spyre Therapeutics
SYRE
$996M
| $37.3M | 1.32% | 2,313,272 -261,451 | -10% | -$4.22M |
|
23
Praxis Precision Medicines
PRAX
$958M
| $37.1M | 1.31% | 980,894 -348,841 | -26% | -$13.2M |
|
24
argenx
ARGX
$43.6B
| $35.2M | 1.24% | 59,510 -7,961 | -12% | -$4.71M |
|
25
Astria Therapeutics
ATXS
$349M
| $34.6M | 1.22% | 6,485,420 | – | – |
|